收藏切换
Pecanthines A–C, unprecedented dimeric β-carboline alkaloids from the seeds of Peganum harmala
收藏切换
PDF
Qing Tanga, b, Kai Zhaoa, b, Hui-Hui Zhua, b, Qiang Lina, b, Hai-Yue Zhaoa, b, Wei-Xuan Zhenga, b, Zhong-Nan Wud, Hao Wanga, Guo-Cai Wanga, b, Yu-Bo Zhanga, c
Chinese Chemical Letters | 2026, 37(10) : 112172
Less
收藏切换
Chinese Chemical Letters | 2026, 37(10): 112172
• Communication •
Pecanthines A–C, unprecedented dimeric β-carboline alkaloids from the seeds of Peganum harmala
Full
Qing Tanga, b, Kai Zhaoa, b, Hui-Hui Zhua, b, Qiang Lina, b, Hai-Yue Zhaoa, b, Wei-Xuan Zhenga, b, Zhong-Nan Wud, Hao Wanga, Guo-Cai Wanga, b, Yu-Bo Zhanga, c
Affiliations
  • aState Key Laboratory of Bioactive Molecules and Druggability Assessment, and Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
  • bInstitute of Traditional Chinese Medicine & Natural Products, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
  • cGuangdong Clinical Translational Center for Targeted Drug, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou 510632, China
  • dGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan 523808, China
About Author:

1

These authors contributed equally to this work.

CRediT authorship contribution statement

Qing Tang: Writing – original draft, Software, Investigation, Data curation, Conceptualization.

Kai Zhao: Validation, Resources, Investigation, Data curation.

Hui-Hui Zhu: Software, Investigation, Formal analysis.

Qiang Lin: Resources.

Hai-Yue Zhao: Validation.

Wei-Xuan Zheng: Software.

Zhong-Nan Wu: Software, Resources.

Hao Wang: Methodology, Investigation.

Guo-Cai Wang: Writing – review & editing, Supervision, Project administration, Investigation, Funding acquisition, Data curation.

Yu-Bo Zhang: Writing – review & editing, Writing – original draft, Visualization, Project administration.

Published: 2026-10-15 doi: 10.1016/j.cclet.2025.112172
Outline
收藏切换

Three novel β-carboline alkaloid dimers, pecanthines A–C (1−3), featuring unprecedented 6/5/6/6–5/6 and 6/5/6/6/5/6 polycyclic frameworks, were isolated from the seeds of Peganum harmala. Their structures were elucidated by spectroscopic analyses and X-ray diffraction. Notably, compounds 1 and 2 represent the first heterodimeric alkaloids merging canthin-6-one and melatonin-type scaffolds, with 1 additionally displaying neuroprotective activity. In addition, a gram-scale synthesis of 3 was achieved in six steps, leveraging a key acyl-ketene imine condensation and Suzuki coupling. Biological evaluation revealed that 3 acts as a new topoisomerase Ⅰ (Topo Ⅰ) inhibitor, exhibiting remarkable antiproliferative activity. Mechanistic studies demonstrated that 3 induces DNA damage, triggering apoptosis and cell cycle arrest in cancer cells. The discovery and gram-scale synthesis of 3 provide a promising lead compound and a novel molecular scaffold for anticancer drug development.

Peganum harmala  /  β-Carboline alkaloid  /  Structural revision  /  Topo Ⅰ inhibition  /  Neuroprotective activity
Qing Tang, Kai Zhao, Hui-Hui Zhu, Qiang Lin, Hai-Yue Zhao, Wei-Xuan Zheng, Zhong-Nan Wu, Hao Wang, Guo-Cai Wang, Yu-Bo Zhang. Pecanthines A–C, unprecedented dimeric β-carboline alkaloids from the seeds of Peganum harmala[J]. Chinese Chemical Letters, 2026 , 37 (10) : 112172 - . DOI: 10.1016/j.cclet.2025.112172
DNA topoisomerase Ⅰ (Topo Ⅰ), a pivotal enzyme orchestrating DNA replication and transcription, is a validated drug target for cancer therapy [1,2]. Topo Ⅰ inhibitors exert their therapeutic effects by stabilizing the DNA-Topo Ⅰ cleavable complex, thereby preventing DNA religation and subsequently inducing DNA damage and tumor cell apoptosis [3–5]. Currently, the clinical use of Topo Ⅰ inhibitors is largely restricted to camptothecin derivatives such as irinotecan and topotecan [6,7]. Although these agents demonstrate significant efficacy against various malignancies, their clinical utility is substantially limited by dose-limiting toxicities and acquired drug resistance, which severely compromise long-term therapeutic outcomes [8–11]. Therefore, there is an urgent need for Topo Ⅰ inhibitors with novel chemical scaffolds.
β-Carboline alkaloids are nitrogen-containing heterocycles biosynthesized from tryptophan with a unique tricyclic pyrido[3,4-b]indole skeleton [12]. This structure is associated with a range of pharmacological activities, with its notable antitumor potential attracting significant attention [12–15]. Among natural sources, plants of the Peganum genus have been identified as exceptionally rich repositories of structurally diverse β-carboline derivatives [16]. Critically, many of these compounds, such as harmine and its analogs, have been identified as Topo Ⅰ inhibitors, making them a key focus for phytochemists and medicinal chemists [17–20].
The seeds of Peganum harmala have been traditionally employed in Chinese folk medicine for the treatment of various ailments, including cancer, rheumatism, cough, and asthma [21–24]. In a previous study, we reported the isolation of new β-carboline alkaloids [24,25]. As a part of our ongoing research, three novel long conjugated β-carboline alkaloids, pecanthines A–C (1−3), were isolated from the seeds of P. harmala (Fig. 1). Their structures were elucidated by spectroscopic analyses and X-ray diffraction. Compounds 1 and 2 represent the first heterodimeric alkaloids merging canthin-6-one and melatonin-type scaffolds. More strikingly, the structure of peganumium B reported from the seeds of P. harmala was revised to be compound 3 (Fig. 1) [26]. Herein, we report the isolation, structural elucidation, hypothetical biogenetic pathway, and biological evaluation of 1–3. Meanwhile, the first gram-scale synthesis of 3 was achieved, further confirming the correctness of the structure.
Pecanthine A (1) was isolated as pink needle-shaped crystals. The molecular formula of 1 was established to be C28H24N4O4 from its high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) data (m/z 481.1872 [M + H]+, calcd. for C28H25N4O4 481.1870). The 1H and 13C nuclear magnetic resonance (NMR) spectra data showed the presence of two AMX spin systems [δH 8.32 (1H, d, J = 8.7 Hz), δH 8.16 (1H, d, J = 2.4 Hz), δH 7.56 (1H, d, J = 8.7 Hz), δH 7.24 (1H, dd, J = 8.7, 2.4 Hz), δH 6.97 (1H, d, J = 2.3 Hz), δH 6.73 (1H, dd, J = 8.7, 2.3 Hz)], three aromatic protons [δH 8.83 (1H, d, J = 5.0 Hz), δH 8.20 (1H, d, J = 5.0 Hz), δH 8.15 (1H, s)], two methoxys [δH 3.94 and 3.80 (each 3H, s); δC 55.9 and 55.2], a methyl [δH 1.71 (3H, s); δC 22.6], and an indole NH signal [δH 11.14 (1H, s)]. The above data indicated that 1 was a dimeric β-carboline alkaloid. The 1H and 13C NMR data of 1 were definitively assigned by integrating 2D NMR experiments, as documented in Table S1 (Supporting information).
In the 1H–1H COSY spectrum, the correlations between H-3 and H-4, between H-7 and H-8, between H-5′ and H-6′, and between H2–11′ (δH 3.34) and H2–10′ (δH 2.98)/NH-12′ (δH 8.00) indicated the presence of four spin systems (C-3 to C-4, C-7 to C-8, C-5′ to C-6′, and C-10′ to N-12′) in 1 (Fig. 2). In the heteronuclear multiple bond correlation (HMBC) spectrum, correlations between H-3 and C-1/C-5, between H-4 and C-6/C-13, between H-7 and C-5/C-9/C-11, between H-8 and C-6/C-10, between H-10 and C-6, between H-14 and C-13/C-16, as well as between 9–OCH3 and C-9 suggested the existence of a 9-methoxycanthin-6-one alkaloid unit 1a (Fig. 2). The HMBC correlations between H-5′ and C-3′/C-7′/C-9′, between H-6′ and C-4′/C-8′, between H-8′ and C-4′, between H2–10′ and C-2′/C-4′, between H2–11′ and C-3′/C-13′, H3–14′ and C-13′, between 7′–OCH3 and C-7′, as well as between NH-1′ and C-3′/C-4′ suggested the presence of a melatonin-type unit 1b (Fig. 2). Furthermore, the HMBC correlations between H-14 and C-2′, and between NH-1′ and C-15 implied that the substructures unit 1a and unit 1b were connected through C-15–C-2′ bonds. Subsequently, crystals of 1 for single-crystal X-ray diffraction were acquired from CH3OH–CH2Cl2 (1:1). Thus, compound 1 was defined as an unprecedented heterodimer alkaloid and further determined by single-crystal X-ray diffraction (Cu Kα) analysis (Fig. 3).
The molecular formula of 2 was determined to be C27H22N4O4 based on its HR-ESI-MS data (m/z 467.1711 [M + H]+, calcd. for C27H23N4O4, 467.1714). Analysis of the 1H and 13C NMR spectra of 2 was similar to those of 1, except for the absence of a methyl signal (δC 22.6, C-14′). The structure was supported by the 1H–1H correlation spectroscopy (COSY) correlation between NH-12′ and H-13′, as well as the HMBC correlations between H-13′ and C-11′, between H2–11′ and C-13′ (Fig. S1 in Supporting information). Thus, compound 2 was elucidated and named pecanthine B.
Pecanthine C (3) was yielded as yellow powder. The molecular formula of 3 was deduced to be C24H21N3O2 on the basis of its HR-ESI-MS at m/z 384.1709 [M + H]+ (calcd. for C24H22N3O2: 384.1707). The UV spectrum of 3 exhibited absorption maxima at 205, 223, 280, 310 and 432 nm. Analysis of the 1H and 13C NMR spectra of 3 revealed the presence of two AMX spin systems [δH 7.91 (1H, d, J = 8.6 Hz), δH 7.53 (1H, d, J = 8.7 Hz), δH 7.10 (1H, d, J = 2.3 Hz), δH 6.92 (1H, d, J = 2.2 Hz), δH 6.77 (1H, dd, J = 8.7, 2.2 Hz), δH 6.74 (1H, dd, J = 8.6, 2.3 Hz)], two methoxyls [δH 3.84 and 3.83 (each 3H, s); δH 55.1 and 55.3], a methyl [δH 2.82 (3H, s); δH 19.6], and an indole NH signal [δH 11.73 (1H, s)]. Comprehensive analysis of 1H–1H COSY, heteronuclear single quantum coherence (HSQC), and HMBC spectra of 3 resulted in the unambiguous assignment of its 1H and 13C NMR signals as shown in Table S3.
In the 1H–1H COSY spectrum, the correlations between H2–3 (δH 4.92) and H2–4 (δH 3.26), between H-7 and H-8, and between H-5′ and H-6′ indicated the presence of three spin systems (C-3 to C-4, C-7 to C-8, and C-5′ to C-6′) in 3 (Fig. 2). In the HMBC spectrum, correlations between H2–3 and C-1/C-5, between H2–4 and C-6/C-13, between H-7 and C-5/C-9/C-11, between H-8 and C-6/C-10, between H-10 and C-6, between H-14 and C-1/C-13, between 9–OCH3 and C-9, as well as between 12-NH and C-5/C-6 suggested the existence of a harmaline unit 3a (Fig. 2). The HMBC correlations between H-5′ and C-3′/C-7′/C-9′, between H-6′ and C-8′, between H-8′ and C-4′, between H3–11′ and C-3′/C-10′, as well as between 7′–OCH3 and C-7′ suggested the presence of a 3-ethylidene-indole unit 3b (Fig. 2). Furthermore, the HMBC correlations between H2–3 and C-2′, between H-14 and C-3′, and between H3–11′ and C-14 indicated that the substructures 3a and 3b were connected through N-2–C-2′ and C-14–C-10′ bonds. Therefore, the planar structure of 3 was established as a unique long conjugated 6/5/6/6/5/6 fused six-ring system.
Peganumium B, recently reported from the seeds of P. harmala as a β-carboline dimer with one novel long conjugated structure, has attracted our attention [26]. Interestingly, compound 3 and peganumium B share identical molecular weights and NMR data, prompting us to re-evaluate peganumium B’s structure. In the original literature, the authors deduced peganumium B as a β-carboline dimer based on NMR analysis. They further identified unit a as harmaline through HMBC spectroscopy, which is consistent with our analysis of 3 in this study. Subsequently, the linkage between units a and b was inferred from chemical shifts and HMBC correlations. However, we have found that the HMBC spectrum of peganumium B exhibits strong cross-peaks for H2–3/C-2′, H-14/C-11′, and H3–11′/C-14 and C-3′ (Fig. S2 in Supporting information), which were not reported in the original study [26]. These correlations perfectly match those of 3, where each pair of atoms is separated by three bonds, whereas in peganumium B, they would be separated by four or five bonds (Fig. 4). Thus, a comprehensive re-evaluation of the spectroscopic data led to the revision of peganumium B as structure 3.
Compounds 1–3 represent two novel classes of dimeric β-carboline alkaloid analogues. The plausible biogenetic pathway of 1–3 could be proposed based on the findings of key biogenetic precursors in the plant (Scheme 1). The biosynthesis initiates with a Mannich reaction between tryptamine and 2-ketoglutaric acid, followed by successive oxidation, methoxylation, and ring condensation to afford the pivotal precursor ⅰ [27,28]. Dimerization of ⅰ with intermediate ⅱa/ⅱb through nucleophilic addition-elimination accounts for the formation of 1 and 2. As for compound 3, its source can be traced back to its precursor, harmaline. First, harmaline (4) undergoes a Michael addition with crotonyl-CoA, followed by intramolecular condensation to afford the key intermediate ⅲ [29,30]. Subsequent oxidation of ⅲ yields intermediate ⅳ, which then engages in a Claisen reaction with anthranilic acid to generate the dehydrated intermediate ⅴ [31]. Finally, 3 is formed through Schiff reaction and methoxylation.
Following the structural revision of peganumium B to 3 and unsuccessful attempts to obtain X-ray-quality crystals, we designed a biomimetic synthesis of 3 according to the biogenic pathway (Scheme 2). The synthesis commenced with harmaline (4) from P. harmala seeds. Using commercially available Meldrum’s acid derivative 6 as an acylketene source, the key intermediate 7 was synthesized in 77% yield [32]. Subsequent Boc protection of the indole NH followed by iodination at the α-position of the carbonyl group afforded intermediate 8 in 83% yield over two steps. Next, a Suzuki-Miyaura coupling of 8 with boronic ester 9 was performed using Pd(dppf)Cl2 and K2CO3 in 1,4-dioxane at 100 ℃, affording the desired 10 in 90% yield. Subsequent reduction with iron powder and NH4Cl cleanly afforded intermediate 11 in 96% yield. The final transformation involved POCl3-mediated intramolecular cyclization under reflux conditions, simultaneously effecting N-Boc deprotection. Ammonia workup delivered 3 in 87% yield on gram scale. The 1H and 13C NMR spectra of synthetic 3 matched those of the natural isolate.
β-Carboline alkaloids have attracted considerable attention due to their notable neuroprotective and antitumor activities. Our study demonstrated that compound 1 exhibited dose-dependent neuroprotective effects in an L-glutamate-induced HT-22 cell model (Fig. S3 in Supporting information). Meanwhile, compound 3 displayed significant cytotoxicity against PC-9 and H1299 cells, with the half maximal inhibitory concentration (IC50) values of 0.856 ± 0.13 and 1.312 ± 0.08 µmol/L, respectively (Fig. 5a). Colony formation assays (Figs. 5b and c) and EdU proliferation assays (Figs. S4a and b in Supporting information) revealed that compound 3 effectively suppressed tumor cell clonogenicity and DNA synthesis. Furthermore, wound healing and transwell invasion assays confirmed that 3 significantly inhibited the migratory and invasive capabilities of PC-9 cells (Figs. S4c–g in Supporting information).
To elucidate the anti-tumor molecular mechanism of compound 3, we focused on Topo Ⅰ, a classic anti-tumor target. The results of relaxation experiments showed that 3 had significantly better inhibitory activity against Topo Ⅰ than the positive control drug camptothecin (Fig. 5d). Molecular docking analysis revealed that 3 formed hydrogen bond interactions with Topo Ⅰ and produced π-π stacking effects with DNA base pairs (Fig. 5e). These molecular interactions were the structural basis for its inhibitory activity against Topo Ⅰ. Given that compound 3 has potent Topo Ⅰ inhibition and antiproliferative activity, we further examined its effect on DNA damage. Immunofluorescence detection and Western blot revealed that the expression level of γ-H2AX, a DNA damage marker, was significantly increased in PC-9 cells treated with 3 (Figs. 5f–h). Flow cytometry analysis showed that 3 could arrest the PC-9 cell cycle at the S phase (Figs. 5i and j) and significantly induce cell apoptosis (Figs. 5k–m).
In summary, three novel long-conjugated β-carboline alkaloids, pecanthines A–C (1–3), were isolated from the seeds of P. harmala. Compounds 1 and 2 represent the first heterodimeric alkaloids merging canthin-6-one and melatonin-type scaffolds. The structure of peganumium B reported from the seeds of P. harmala was revised to be compound 3. Meanwhile, a gram-scale synthesis of 3 was achieved in six steps, leveraging a key acyl-ketene imine condensation and Suzuki coupling, further corroborating its revised structure based on NMR analysis. The bioassays revealed that compound 1 exhibited dose-dependent neuroprotective effects in an L-glutamate-induced HT-22 cell model. Compound 3 displayed significant cytotoxicity against PC-9 and H1299 cells, with IC50 values of 0.856 ± 0.13 and 1.312 ± 0.08 µmol/L, respectively. Significantly, compound 3 inhibits tumor cell proliferation by suppressing Topo Ⅰ activity, inducing DNA damage, arresting the cell cycle, and promoting apoptosis (Fig. 5n). This finding provides a new structural template for the development of Topo Ⅰ inhibitors.
1
Y. Pommier, Chem. Rev. 109 (2009) 2894–2902.
2
Y. Pommier, A. Nussenzweig, S. Takeda, et al., Nat. Rev. Mol. Cell. Biol. 23 (2022) 407–427.
3
K. Hevener, T.A. Verstak, K.E. Lutat, et al., Acta. Pharm. Sin. B 8 (2018) 844–861.
4
A.M. Elshazly, P.A. Wright, J. Xu, et al., Autophagy Rep 2 (2023) 1–16.
5
F. Lei, Y. Xiong, Y. Wang, et al., J. Med. Chem. 65 (2022) 7975–7992.
6
X. Deng, Y. Wang, X. Yang, et al., J. Med. Chem. 68 (2025) 3518–3546.
7
H. Wang, X. Bai, Y. Huang, et al., Chin. Chem. Lett. 34 (2023) 107671.
8
X. Wei, Z.W. Luo, G.Q. Zhang, et al., Chin. Chem. Lett. 37 (2026) 111048.
9
S. Kumar, M.Y. Sherman, Int. J. Mol. Sci. 24 (2023) 7233.
10
B. Wang, S. Wu, S. Jia, et al., J. Med. Chem. 67 (2024) 14155–14174.
11
M. Cushman, J. Med. Chem. 64 (2021) 17572–17600.
12
A. Beato, A. Gori, B. Boucherle, et al., J. Med. Chem. 64 (2021) 1392–1422.
13
L. Yu, N. Shen, J. Ren, et al., Fitoterapia 180 (2025) 106326.
14
Q. Liu, C. Yang, J. Qi, et al., Chem. Biodivers. 22 (2025) e202402953.
15
M.U. Rehman, Y. Zuo, N. Tu, et al., Eur. J. Med. Chem. 287 (2025) 117350.
16
F.A. Khan, A. Maalik, Z. Iqbal, et al., Eur. J. Pharmacol. 721 (2013) 391–394.
17
Y.L. Guo, J.W. Yu, Y. Cao, et al., Eur. J. Med. Chem. 265 (2024) 116061.
18
R. Cao, W. Peng, H. Chen, et al., Biochem. Biophys. Res. Commun. 338 (2005) 1557–1563.
19
K.B. Wang, Y.T. Di, Y. Bao, et al., Org. Lett. 16 (2014) 4028–4031.
20
K.B. Wang, D.H. Li, P. Hu, et al., Org. Lett. 18 (2016) 3398–3401.
21
R. Cao, W. Peng, Z. Wang, et al., Curr. Med. Chem. 14 (2007) 479–500.
22
K.B. Wang, D.H. Li, Y. Bao, et al., J. Nat. Prod. 80 (2017) 551–559.
23
S. Li, X. Cheng, C. Wang, J. Ethnopharmacol. 203 (2017) 127–162.
24
Z.N. Wu, N.H. Chen, Q. Tang, et al., Org. Lett. 22 (2020) 7310–7314.
25
Z.N. Wu, Y.B. Zhang, G.C. Wang, et al., Fitoterapia 179 (2024) 106237.
26
Y. Liu, C. Liu, H. Guo, et al., Chin. Chem. Lett. 36 (2025) 110558.
27
G. Cebrián-Torrejón, N. Mackiewicz, R.P. Vázquez-Manrique, et al., Eur. J. Org. Chem. 2013 (2013) 5821–5828.
28
J. Dai, N. Li, J. Wang, et al., Molecules 21 (2016) 493.
29
D. Scharnagel, J. Goller, N. Deibl, Angew. Chem. Int. Ed. 57 (2018) 2432–2435.
30
X. Zhang, Nat. Prod. Rep. 41 (2024) 784–812.
31
T.M. Lv, D.L. Chen, J.J. Liang, et al., Org. Lett. 23 (2021) 7231–7235.
32
N. Pemberton, L. Jakobsson, F. Almqvist, Org. Lett. 8 (2006) 935–938.
Year 2026 volume 37 Issue 10
PDF
98
53
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2025.112172
  • Receive Date:2025-08-08
  • Online Date:2026-10-27
  • Published:2026-10-15
Article Data
Affiliations
History
  • Received:2025-08-08
  • Revised:2025-11-23
  • Accepted:2025-11-25
Affiliations
    aState Key Laboratory of Bioactive Molecules and Druggability Assessment, and Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China
    bInstitute of Traditional Chinese Medicine & Natural Products, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou 510632, China
    cGuangdong Clinical Translational Center for Targeted Drug, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou 510632, China
    dGuangdong Provincial Key Laboratory of Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan 523808, China

Corresponding:

*

E-mail addresses: (H. Wang)
(Y.-B. Zhang)
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2025.112172
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT